S Abbasian, A Ghotaslou, A Ghasemi, F Nadali,
Volume 7, Issue 4 (7-2015)
Abstract
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been detected to have increased expression in many cancers. We aimed to determine if SIRT1expression could play a role in the emergence of drug resistance in patients with chronic myeloid leukemia being treated with imatinib mesylate. Methods: 48 patients with chronic myeloid leukemia referred to Dr. Shariati Hospital, Tehran, Iran, were studied. A venous blood sample of patients was collected, RNA was extracted and then cDNA were synthesized. SIRT1 gene expression was done by real-time PCR. The ratio of SIRT1 expression to ABL control gene was calculated. After calculation of CT for target gene and control gene, &DeltaCT was calculated. The results of SIRT1 expression levels in patients with chronic phase of CML were compared with that of the control group. Results: 48 patients with chronic myeloid leukemia aged 15-64 years (mean: 40 years) were enrolled. 59% of the participants were men. The highest and lowest mean BCR-ABL expressions in drug-resistant patients were 1% and 57%, respectively. The results of analyzing the value of &DeltaCT for SIRT1 gene revealed that patients who were drug-resistant to imatinib mesylate had a lower value of &DeltaCT for SIRT1 than those who were not drug-resistant (P<0.05). Conclusion: SIRT1 gene expression in patients resistant to imatinib mesylate was significantly higher than patients who were not drug-resistant.
Morteza Bagheri, Isa Abdi Rad, Davood Maleki, Ali Eishi, Nasim Valizadeh,
Volume 10, Issue 2 (6-2018)
Abstract
Background: The Philadelphia chromosome (Ph) characterized by t (9; 22) (q34; q11.2) is a reciprocal translocation giving rise to a chimeric BCR-ABL fusion gene. Incidence of Ph chromosome is over 98% in Patients with Chronic Myeloid Leukemia (CML) and around 20% in acute lymphoblastic leukemia (ALL). The finding of this fusion gene is essential for diagnosis of CML by detection of various fusion transcripts such as b2a2 and b3a2 transcripts and Ph positive ALL by detection of e1a2 (p190) transcripts. We conducted this study to determine the frequency of various BCR-ABL fusion transcripts in the west Azerbaijani patients with CML.
Methods: RNA was isolated from peripheral blood samples by standard protocols. BCR-ABL fusion gene detection was carried out with one-step multiplex RT-PCR in 41 west Azerbaijani patients with CML.
Results: Among patients with CML, the frequencies of b2a2 and b3a2 transcripts were 52.5% and 12.5%, respectively. Co-expression of b3a2 and b2a2 transcripts was found in 12.5% of the patients.
Conclusion: The findings of this study showed that multiplex RT-PCR is a suitable technique to identify the typical BCR-ABL fusion transcripts in the west Azerbaijani patients with CML. Atypical transcripts possibly run away while using multiplex PCR.
